Esperion Therapeutics (ESPR) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a report published on Thursday, BidAskClub reports.

ESPR has been the topic of a number of other reports. ValuEngine upgraded Esperion Therapeutics from a hold rating to a buy rating in a report on Friday, May 3rd. Stifel Nicolaus restated a buy rating and issued a $112.00 price objective on shares of Esperion Therapeutics in a report on Friday, March 29th. Credit Suisse Group raised their price objective on Esperion Therapeutics from $79.00 to $90.00 and gave the stock an outperform rating in a report on Monday, May 6th. Zacks Investment Research downgraded Esperion Therapeutics from a hold rating to a sell rating in a report on Friday, February 8th. Finally, Northland Securities restated a buy rating and issued a $65.00 price objective on shares of Esperion Therapeutics in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Esperion Therapeutics has a consensus rating of Buy and an average price target of $75.42.

NASDAQ:ESPR traded down $0.66 during mid-day trading on Thursday, reaching $50.17. The company’s stock had a trading volume of 885,834 shares, compared to its average volume of 673,330. Esperion Therapeutics has a twelve month low of $35.80 and a twelve month high of $60.99. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -6.65 and a beta of 2.11.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $2.43. The firm had revenue of $145.42 million during the quarter, compared to analysts’ expectations of $69.35 million. During the same quarter last year, the business earned ($1.73) earnings per share. On average, equities analysts predict that Esperion Therapeutics will post -3.14 earnings per share for the current year.

In related news, CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average cost of $48.73 per share, for a total transaction of $243,650.00. Following the acquisition, the chief executive officer now owns 51,163 shares in the company, valued at approximately $2,493,172.99. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $50.06, for a total value of $1,251,500.00. Following the sale, the director now owns 548,726 shares in the company, valued at $27,469,223.56. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 65,000 shares of company stock worth $3,155,550 and have sold 48,329 shares worth $2,280,206. Company insiders own 7.70% of the company’s stock.

Several large investors have recently made changes to their positions in ESPR. Hsbc Holdings PLC purchased a new stake in shares of Esperion Therapeutics during the 4th quarter valued at about $11,067,000. FMR LLC increased its holdings in Esperion Therapeutics by 43.8% during the 4th quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock worth $34,007,000 after purchasing an additional 225,205 shares during the last quarter. Spark Investment Management LLC increased its holdings in Esperion Therapeutics by 72.1% during the 1st quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock worth $15,694,000 after purchasing an additional 163,800 shares during the last quarter. Rhenman & Partners Asset Management AB increased its holdings in Esperion Therapeutics by 35.5% during the 1st quarter. Rhenman & Partners Asset Management AB now owns 479,767 shares of the biopharmaceutical company’s stock worth $19,263,000 after purchasing an additional 125,806 shares during the last quarter. Finally, Norges Bank purchased a new stake in Esperion Therapeutics during the 4th quarter worth approximately $5,536,000.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: Trading Penny Stocks

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.